Transplantation of mouse embryonic stem cell after middle cerebral artery occlusion

Lee, Tae-Hoon; Lee, Yoon-Seok

doi:10.1590/s0102-86502012000400009

Cited by 21 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Murine ESCs implanted into the contralateral hemisphere following transient cerebral ischemia migrated along the corpus callosum to the ventricular walls, massively populating the border zone of the damaged brain tissue (Hoehn et al, 2002), and correlated with improvements in histological and behavioral outcomes (Nagai et al, 2010; Yanagisawa et al, 2006). Grafted mouse ESCs also form synaptic connection in the recipient brain (Tae-Hoon and Yoon-Seok, 2012). …”

Section: Cellular Therapies From Different Cell Sourcesmentioning

confidence: 99%

Cell based therapies for ischemic stroke: From basic science to bedside

Liu

Yan

et al. 2014

Progress in Neurobiology

164

141

View full text Add to dashboard Cite

Cell therapy is emerging as a viable therapy to restore neurological function after stroke. Many types of stem/progenitor cells from different sources have been explored for their feasibility and efficacy for the treatment of stroke. Transplanted cells not only have the potential to replace the lost circuitry, but also produce growth and trophic factors, or stimulate the release of such factors from host brain cells, thereby enhancing endogenous brain repair processes. Although stem/progenitor cells have shown a promising role in ischemic stroke in experimental studies as well as initial clinical pilot studies, cellular therapy is still at an early stage in humans. Many critical issues need to be addressed including the therapeutic time window, cell type selection, delivery route, and in vivo monitoring of their migration pattern. This review attempts to provide a comprehensive synopsis of preclinical evidence and clinical experience of various donor cell types, their restorative mechanisms, delivery routes, imaging strategies, future prospects and challenges for translating cell therapies as a neurorestorative regimen in clinical applications.

show abstract

Section: Cellular Therapies From Different Cell Sourcesmentioning

confidence: 99%

Cell based therapies for ischemic stroke: From basic science to bedside

Liu

Yan

et al. 2014

Progress in Neurobiology

164

141

View full text Add to dashboard Cite

show abstract

“…Induced pluripotent stem cells ( 26 ), embryonic stem cells ( 27 ), neural stem cells ( 28 ), bone marrow-derived mesenchymal stem cells ( 29 ) and DPSCs ( 30 ) exhibit neuroprotective effects in ischemic stroke animal models. DPSCs are easily harvested, cultured, amplified and cryo-preserved.…”

Section: Discussionmentioning

confidence: 99%

Intravenous administration of DPSCs and BDNF improves neurological performance in rats with focal cerebral ischemia

Zhang

Zhou

et al. 2018

Int J Mol Med

View full text Add to dashboard Cite

Dental pulp stem cells (DPSCs) are considered as an ideal stem cell source for the treatment of neurological diseases. In this study, we evaluated the therapeutic potency of DPSCs and brain-derived neurotrophic factor (BDNF) in focal cerebral ischemia using animal models. Following middle cerebral artery occlusion (MCAO), rats were randomized into four groups: the BDNF, DPSCs, DPSCs+BDNF and the controls injected with saline. DPSCs were transplanted and BDNF was injected into the DPSCs+BDNF group via the tail vein. The fate of the transplanted DPSCs in rat brains was evaluated using immunofluorescence, immunohistochemistry, western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR). Adhesive removal tests and the modified neurological severity scores were used to estimate the restoration of neurological function. Proliferation of intravenously transplanted DPSCs was observed in the peripheral ischemic regions of the MCAO models. A green fluorescent dye PKH67 was used to label cells. PKH67-labeled DPSCs were co-localized with neuronal cell markers and 4′,6-diamidino-2-phenylindole (DAPI). DPSC transplantation combined with BDNF induced the expression of neural differentiation markers such as nestin, doublecortin (DCX) and neuronal specific filament (NF-H), suggesting that BDNF enhances the survival of DPSCs and differentiation into neuronal cells. Treatment with DPSCs combined with BDNF promoted the recovery of neurological function more effectively compared with BDNF injection or DPSC transplantation alone. In conclusion, treatment with DPSCs combined with BDNF enhances neurological recovery after stroke suggesting a novel therapeutic strategy against cerebral ischemia.

show abstract

“…The regenerative capacity of ESC in stroke is related to their ability to give rise to different neuronal and glial elements forming the brain tissues (i.e., neurons, astrocytes, and oligodendrocytes) ( 12 ). Engrafted murine ESCs in cerebral tissue in an ischemic mouse model migrated toward damaged brain areas in the opposite cerebral hemisphere, restored histological and behavioral deficits ( 13 ), and repaired damaged synaptic connections associated with stroke lesions ( 14 ).…”

Section: Embryonic Stem Cellsmentioning

confidence: 99%

Potential of Stem Cell-Based Therapy for Ischemic Stroke

et al. 2018

View full text Add to dashboard Cite

Ischemic stroke is one of the major health problems worldwide. The only FDA approved anti-thrombotic drug for acute ischemic stroke is the tissue plasminogen activator. Several studies have been devoted to assessing the therapeutic potential of different types of stem cells such as neural stem cells (NSCs), mesenchymal stem cells, embryonic stem cells, and human induced pluripotent stem cell-derived NSCs as treatments for ischemic stroke. The results of these studies are intriguing but many of them have presented conflicting results. Additionally, the mechanism(s) by which engrafted stem/progenitor cells exert their actions are to a large extent unknown. In this review, we will provide a synopsis of different preclinical and clinical studies related to the use of stem cell-based stroke therapy, and explore possible beneficial/detrimental outcomes associated with the use of different types of stem cells. Due to limited/short time window implemented in most of the recorded clinical trials about the use of stem cells as potential therapeutic intervention for stroke, further clinical trials evaluating the efficacy of the intervention in a longer time window after cellular engraftments are still needed.

show abstract

Transplantation of mouse embryonic stem cell after middle cerebral artery occlusion

Cited by 21 publications

References 21 publications

Cell based therapies for ischemic stroke: From basic science to bedside

Cell based therapies for ischemic stroke: From basic science to bedside

Intravenous administration of DPSCs and BDNF improves neurological performance in rats with focal cerebral ischemia

Potential of Stem Cell-Based Therapy for Ischemic Stroke

Contact Info

Product

Resources

About